The nature of relapse in schizophrenia

[1]  P. Buckley,et al.  Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects , 2013, Biological Psychiatry.

[2]  R. Emsley,et al.  Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine , 2013, Brain, Behavior, and Immunity.

[3]  R. Emsley,et al.  Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia , 2013, Journal of clinical psychopharmacology.

[4]  R. Murray,et al.  The Myth of Schizophrenia as a Progressive Brain Disease , 2012, Schizophrenia bulletin.

[5]  S. Stahl,et al.  Glutamate Neurocircuitry: Theoretical Underpinnings in Schizophrenia , 2012, Front. Pharmacol..

[6]  T. Rangaswamy,et al.  Course and outcome of schizophrenia , 2012, International review of psychiatry.

[7]  P. McGorry,et al.  Risk factors for relapse following treatment for first episode psychosis: A systematic review and meta-analysis of longitudinal studies , 2012, Schizophrenia Research.

[8]  Mark Slifstein,et al.  The nature of dopamine dysfunction in schizophrenia and what this means for treatment. , 2012, Archives of general psychiatry.

[9]  John M. Davis,et al.  Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis , 2012, The Lancet.

[10]  R. Emsley,et al.  Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia , 2012, Schizophrenia Research.

[11]  R. Emsley,et al.  Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. , 2012, The Journal of clinical psychiatry.

[12]  B. Leonard,et al.  The metabolic syndrome in schizophrenia: is inflammation a contributing cause? , 2012, Journal of psychopharmacology.

[13]  M. Mimura,et al.  Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms , 2012, Schizophrenia Research.

[14]  B. Harvey,et al.  Author ' s response to reviews Title : The nature of relapse in schizophrenia , 2012 .

[15]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[16]  B. Miller,et al.  Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review , 2011, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[17]  J. Tiihonen,et al.  A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. , 2011, The American journal of psychiatry.

[18]  R. Kahn,et al.  Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: Results from an aborted randomised trial , 2011, International journal of psychiatry in clinical practice.

[19]  H. Möller,et al.  Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. , 2011, The Journal of clinical psychiatry.

[20]  S. Kapur,et al.  How antipsychotics work—From receptors to reality , 2011, NeuroRX.

[21]  W. Honer,et al.  Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial , 2010, BMJ : British Medical Journal.

[22]  S. Leucht,et al.  Elaboration on the Early-Onset Hypothesis of Antipsychotic Drug Action: Treatment Response Trajectories , 2010, Biological Psychiatry.

[23]  S. Kapur,et al.  The dopamine hypothesis of schizophrenia: version III--the final common pathway. , 2009, Schizophrenia bulletin.

[24]  Jolene R. Bostwick,et al.  Antipsychotic‐Induced Hyperprolactinemia , 2009, Pharmacotherapy.

[25]  B. Miller.  A Review of Second-Generation Antipsychotic Discontinuation in First-Episode Psychosis , 2008, Journal of psychiatric practice.

[26]  M. Cuénod,et al.  N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial , 2008, Biological Psychiatry.

[27]  D. Wiersma,et al.  GUIDED DISCONTINUATION VERSUS MAINTENANCE TREATMENT IN REMITTED FIRST EPISODE PSYCHOSIS: RELAPSE RATES AND FUNCTIONAL OUTCOME , 2008, Schizophrenia Research.

[28]  Allan R. Sampson,et al.  Effect of Chronic Antipsychotic Exposure on Astrocyte and Oligodendrocyte Numbers in Macaque Monkeys , 2008, Biological Psychiatry.

[29]  R. Emsley,et al.  Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis: A Preliminary Study , 2008, Journal of clinical psychopharmacology.

[30]  C. Correll,et al.  Tardive dyskinesia and new antipsychotics , 2008, Current opinion in psychiatry.

[31]  J. Lieberman,et al.  Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. , 2008, The Journal of clinical psychiatry.

[32]  M. Berk,et al.  Effect of Chronic N-Acetyl Cysteine Administration on Oxidative Status in the Presence and Absence of Induced Oxidative Stress in Rat Striatum , 2008, Neurochemical Research.

[33]  J. Kane,et al.  Treatment strategies to prevent relapse and encourage remission. , 2007, The Journal of clinical psychiatry.

[34]  W. Heiden,et al.  Course and Outcome of Schizophrenia , 2007 .

[35]  W. Gaebel,et al.  Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia , 2007, Schizophrenia Research.

[36]  S. Kapur,et al.  “Breakthrough” Dopamine Supersensitivity during Ongoing Antipsychotic Treatment Leads to Treatment Failure over Time , 2007, The Journal of Neuroscience.

[37]  J. Newcomer,et al.  Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. , 2007, The Journal of clinical psychiatry.

[38]  D. Wiersma,et al.  Guided Discontinuation Versus Maintenance Treatment in Remitted First-Episode Psychosis: Relapse Rates and Functional Outcome , 2007 .

[39]  Z. Herman,et al.  Cytokines in schizophrenia and the effects of antipsychotic drugs , 2006, Brain, Behavior, and Immunity.

[40]  J. Moncrieff,et al.  Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal‐related relapse , 2006, Acta psychiatrica Scandinavica.

[41]  R. Emsley,et al.  Time course for antipsychotic treatment response in first-episode schizophrenia. , 2006, The American journal of psychiatry.

[42]  T. McGlashan,et al.  Is active psychosis neurotoxic? , 2005, Schizophrenia bulletin.

[43]  D. Rawlings,et al.  Early warning signs of relapse following a first episode of psychosis , 2005, Schizophrenia Research.

[44]  Peter B. Jones,et al.  Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. , 2005, Archives of general psychiatry.

[45]  J. Kane,et al.  Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended , 2005, Biological Psychiatry.

[46]  S. Nyberg,et al.  Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. , 2005, The international journal of neuropsychopharmacology.

[47]  N. Tarrier,et al.  Prodromal signs of relapse in schizophrenia , 1991, Social Psychiatry and Psychiatric Epidemiology.

[48]  Dan J Stein,et al.  Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression , 2003, Biological Psychiatry.

[49]  S. Kapur,et al.  Half a century of antipsychotics and still a central role for dopamine D2 receptors , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[50]  B. Harvey,et al.  Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: Reversal with olanzapine , 2003, Behavioural pharmacology.

[51]  S. Kapur,et al.  Delayed onset hypothesis of antipsychotic action — a hypothesis tested and rejected , 2003, Schizophrenia Research.

[52]  S. Kapur.  Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. , 2003, The American journal of psychiatry.

[53]  J. Addington,et al.  Medication adherence of individuals with a first episode of psychosis , 2002, Acta psychiatrica Scandinavica.

[54]  G. Bartzokis,et al.  Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. , 2001, The American journal of psychiatry.

[55]  M. Birchwood,et al.  Early intervention in psychotic relapse. , 2001, Clinical psychology review.

[56]  P. S. Naidu,et al.  Excitatory mechanisms in neuroleptic‐induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide , 2001, Behavioural pharmacology.

[57]  O. Andreassen,et al.  Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats Implications for tardive dyskinesia? , 2000, Progress in Neurobiology.

[58]  B. Harvey,et al.  Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment , 2000, Behavioural Brain Research.

[59]  J. Bartko,et al.  The long-term effects of placebo in patients with chronic schizophrenia , 1999, Biological Psychiatry.

[60]  J. Lieberman,et al.  Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.

[61]  H. Hoek,et al.  Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III. , 1998, The American journal of psychiatry.

[62]  R Giel,et al.  Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. , 1998, Schizophrenia bulletin.

[63]  R. Wyatt.  Research in schizophrenia and the discontinuation of antipsychotic medications. , 1997, Schizophrenia bulletin.

[64]  J. Lieberman,et al.  Psychobiologic Correlates of Treatment Response in Schizophrenia , 1996, Neuropsychopharmacology.

[65]  A. Yung,et al.  The prodromal phase of first-episode psychosis: past and current conceptualizations. , 1996, Schizophrenia bulletin.

[66]  C. Mcallister,et al.  Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. , 1995, The American journal of psychiatry.

[67]  R. Baldessarini,et al.  Neuroleptic withdrawal in schizophrenic patients. , 1995, Archives of general psychiatry.

[68]  D. Jeste,et al.  Neuroleptic withdrawal in schizophrenic patients. A review of the literature. , 1995, Archives of general psychiatry.

[69]  H. Meltzer.  Neuroleptic withdrawal in schizophrenic patients. An idea whose time has come. , 1995, Archives of general psychiatry.

[70]  A. Malla,et al.  Prodromal symptoms of relapse in schizophrenia: a review. , 1995, Schizophrenia bulletin.

[71]  J. Bustillo,et al.  Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. , 1995, Schizophrenia bulletin.

[72]  Yoshinosuke Henmi.  Prodromal Symptoms of Relapse in Schizophrenic Outpatients: Retrospective and Prospective Study , 1993, The Japanese journal of psychiatry and neurology.

[73]  W. Gaebel,et al.  Early Neuroleptic Intervention in Schizophrenia: Are Prodromal Symptoms Valid Predictors of Relapse? , 1993, British Journal of Psychiatry.

[74]  J. Lieberman,et al.  Time course and biologic correlates of treatment response in first-episode schizophrenia. , 1993, Archives of general psychiatry.

[75]  D. Greenberg.  Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association , 1993 .

[76]  R. Wyatt,et al.  Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients , 1992, Biological Psychiatry.

[77]  S. Steingard,et al.  Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. , 1991, Archives of general psychiatry.

[78]  R J Wyatt,et al.  Neuroleptics and the natural course of schizophrenia. , 1991, Schizophrenia bulletin.

[79]  M. Birchwood,et al.  Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation , 1989, Psychological Medicine.

[80]  T. Crow,et al.  II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment , 1986, British Journal of Psychiatry.

[81]  F. Quitkin,et al.  Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. , 1982, Archives of general psychiatry.

[82]  B. Jones,et al.  Drs. Chouinard and Jones Reply , 1980 .

[83]  C. Melville,et al.  Relapse in schizophrenia. , 1980, The American journal of psychiatry.

[84]  B. Jones,et al.  Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. , 1980, The American journal of psychiatry.

[85]  J P Cali,et al.  An idea whose time has come. , 1973, Clinical chemistry.